Sec Form 4 Filing - Lefkowitz Steven W @ CorMedix Inc. - 2016-06-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lefkowitz Steven W 2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O CORMEDIX INC., 1430 US HIGHWAY 206, SUITE 200 3. Date of Earliest Transaction (MM/DD/YY) 06/01/2016 (Street) BEDMINSTER, NJ07921 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, $0.001 par value per share 06/01/2016 M 100,000 A $ 0.68 217,399 D Common Stock, $0.001 par value per share 174,741 I ( 1 ) Wade Capital Corporation Money Purchase Plan Common Stock, $0.001 par value per share 10,000 I ( 1 ) Reporting Person's Wife

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 2.02 ( 2 ) 01/09/2024 Common Stock, $0.001 par value per share 200,000 200,000 D Stock Option (right to buy) $ 2.02 ( 3 ) 01/09/2024 Common Stock, $0.001 par value per share 30,000 30,000 D Swries C-3 Non-Voting Convertible Preferred Stock $ 1 ( 4 ) ( 4 ) Common Stock, $0.001 par value per share 45,000 4,500 D Warrant (right to purchase Common Stock) $ 0.9 ( 5 ) 01/08/2015 01/08/2020 Common Stock, $0.001 par value per share 22,500 22,500 D Series C-3 Non-Voting Convertible Preferred Stock $ 1 ( 5 ) ( 5 ) Common Stock, $0.001 par value per share 30,000 3,000 I ( 1 ) Wade Capital Corporation Money Purchase Plan Warrant (right to purchase Common Stock) $ 0.9 ( 5 ) 01/08/2015 01/08/2020 Common Stock, $0.001 par value per share 15,000 15,000 I ( 1 ) Wade Capital Corporation Money Purchase Plan Stock Option (right to buy) $ 0.9 ( 6 ) 03/20/2023 Common Stock, $0.001 par value per share 120,000 120,000 D Stock Option (right to buy) $ 0.68 06/01/2016 M 100,000 ( 7 ) 12/05/2022 Common Stock, $0.001 par value per share 100,000 $ 0 0 D Stock Option (right to buy) $ 1.1 ( 8 ) 08/11/2021 Common Stock, $0.001 par value per share 30,000 30,000 D Stock Option (right to buy) $ 5.62 ( 3 ) 03/01/2025 Common Stock, $0.001 par value per share 50,000 50,000 D Stock Option (right to buy) $ 1.91 ( 3 ) 09/20/2017 Common Stock, $0.001 par value per share 75,000 75,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lefkowitz Steven W C/O CORMEDIX INC. 1430 US HIGHWAY 206, SUITE 200 BEDMINSTER, NJ07921 X Signatures Alexander M. Donalson by Power of Attorney 06/03/2016 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control). ( 2 )The options vested 100% on January 10, 2014. ( 3 )The options vest in full on the first anniversary of the date of grant. ( 4 )On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock. ( 5 )On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock. ( 6 )These options vest quarterly over two years beginning June 13, 2013. ( 7 )These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013. ( 8 )The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.